Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients

The FDA has signed off Intellia Therapeutics Inc's NTLA investigational new drug (IND) application for NTLA-5001.
Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate.
NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms' Tumor (WT1) antigen for the treatment of all genetic subtypes of acute myeloid leukemia (AML).
Intellia plans to initiate patient screening by the end of 2021 for the Phase 1/2a study evaluating NTLA-5001 in adults with persistent or recurrent AML who have previously received first-line therapy.
The Phase 1/2a study will evaluate the safety, tolerability, cell kinetics, and anti-tumor activity of a single dose of NTLA-5001.
The study will contain a dose escalation and expansion phase, with up to 54 participants.
Price Action: NTLA shares are up 1.44% at $152.73 on the last check Thursday.

Momentum7.87

GrowthNot Available

QualityNot Available

Value31.47

Short

Medium

Long